Karen Adams, MD
Obstetrics/Gynecology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Adams’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G186905 · Current
Licensed to practise in California · since 2023 · expires 2027-06-30 · University of Texas Medical School at Houston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$13,466
Medicare paid this office $13,466 for 90 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 20 | $3,049 | $152 |
| Long return visit (40+ min) | 19 | $2,947 | $155 |
| Short return visit (20+ min) | 20 | $2,138 | $93 |
| Return visit (30+ min) | 12 | $1,466 | $122 |
Who their Medicare patients are
90 Original Medicare patients in 2024. Average age 68 · Under 65 21% · Women 100% · Also on Medicaid 24% · Health risk score 1.13. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 36% · Depression 27% · Cancer 20% · Coronary heart disease 13%.
The office billed $67,502, Medicare allowed $18,087 and paid $13,466; for 113 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 90 | 113 | 68 | 1.13 | $67,502 | $13,466 |
| 2023 | 34 | 36 | 67 | 0.85 | $22,740 | $3,695 |
| 2022 | 53 | 63 | 68 | 0.99 | $15,361 | $3,766 |
| 2021 | 85 | 102 | 69 | 0.99 | $25,234 | $7,573 |
| 2020 | 71 | 83 | 69 | 0.83 | $20,310 | $5,582 |
| 2019 | 80 | 115 | 66 | 1.09 | $22,284 | $6,272 |
| 2018 | 68 | 86 | 69 | 0.85 | $10,472 | $4,965 |
| 2017 | 47 | 57 | 65 | 1.09 | $5,088 | $3,000 |
| 2016 | 35 | 40 | 68 | 0.67 | $3,116 | $1,820 |
| 2015 | 42 | 59 | 65 | 1.01 | $4,888 | $2,474 |
| 2014 | 32 | 41 | 68 | 0.85 | $3,608 | $1,753 |
| 2013 | 32 | 44 | 61 | 1.04 | $4,117 | $1,963 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 12 | $1,596 | $133 |
2022: 1 service
| Short return visit (20+ min) | 16 | $905 | $50 |
2021: 4 services
| Return visit (30+ min) | 20 | $1,489 | $71 |
| New patient visit (45+ min) | 14 | $1,454 | $104 |
| New patient visit (30+ min) | 19 | $1,120 | $59 |
| Short return visit (20+ min) | 12 | $571 | $48 |
2020: 3 services
| Long return visit (40+ min) | 13 | $1,227 | $82 |
| Return visit (30+ min) | 16 | $1,022 | $57 |
| New patient visit (30+ min) | 11 | $574 | $52 |
2019: 3 services
| Return visit (30+ min) | 26 | $1,677 | $51 |
| Short return visit (20+ min) | 21 | $837 | $36 |
| New patient visit (30+ min) | 15 | $734 | $49 |
2018: 3 services
| Return visit (30+ min) | 26 | $1,280 | $49 |
| New patient visit (30+ min) | 21 | $1,113 | $53 |
| Short return visit (20+ min) | 18 | $665 | $37 |
2017: 3 services
| New patient visit (30+ min) | 14 | $857 | $61 |
| Return visit (30+ min) | 13 | $756 | $58 |
| Short return visit (20+ min) | 15 | $572 | $36 |
2016: 2 services
| Return visit (30+ min) | 11 | $560 | $51 |
| New patient visit (30+ min) | 11 | $546 | $50 |
2015: 1 service
| Short return visit (20+ min) | 22 | $691 | $30 |
Medicaid work
$26,143 in 2020
Medicaid paid $26,143 for 274 billed services this clinician did in 2020, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Hospital outpatient clinic visit for assessment and management of a patient | 274 | $26,143 |
| 2020 | 274 | 1 | 39 | $26,143 |
| 2019 | 338 | 1 | 42 | $26,780 |
| 2018 | 443 | 5 | 53 | $34,266 |
See the largest Medicaid services in earlier years
2019
| Hospital outpatient clinic visit for assessment and management of a patient | 338 | $26,780 |
2018
| Hospital outpatient clinic visit for assessment and management of a patient | 394 | $34,262 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 13 | $4 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique | 12 | $0 |
| Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique | 12 | $0 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique | 12 | $0 |
Drugs they prescribed that Part D paid
$32,880
Pharmacies billed $32,880 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 246) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
189 generic and 57 brand-name prescriptions · $32,880 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol (Twice Weekly) | 59 | $6,889 | $117 |
| Estradiol | 54 | $2,646 | $49 |
| Progesterone | 50 | $2,001 | $40 |
| Gabapentin | 16 | $111 | $7 |
Year by year
| 2024 | 246 | 70 | 0% (0) | 23% | $32,880 |
| 2023 | 75 | 46 | 0% (0) | 24% | $10,728 |
| 2022 | 256 | 81 | 0% (0) | 17% | $33,054 |
| 2021 | 296 | 96 | 0% (0) | 20% | $33,372 |
| 2020 | 295 | 77 | 0% (0) | 19% | $34,472 |
| 2019 | 271 | 80 | 0% (0) | 23% | $28,752 |
| 2018 | 200 | 52 | 0% (0) | 26% | $21,351 |
| 2017 | 170 | 41 | 0% (0) | None | $25,339 |
| 2016 | 186 | 43 | 0% (0) | 37% | $22,917 |
| 2015 | 163 | 42 | None | 42% | $20,174 |
| 2014 | 148 | 32 | 0% (0) | 61% | $16,833 |
| 2013 | 116 | 30 | 0% (0) | 69% | $12,144 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Estradiol | 16 | $2,758 | $172 |
| Estradiol (Twice Weekly) | 12 | $2,336 | $195 |
| Progesterone | 13 | $956 | $74 |
2022: 3 drugs
| Estradiol | 77 | $12,555 | $163 |
| Estradiol (Twice Weekly) | 33 | $5,033 | $153 |
| Progesterone | 50 | $2,535 | $51 |
2021: 5 drugs
| Estradiol | 66 | $8,277 | $125 |
| Estradiol (Twice Weekly) | 26 | $4,326 | $166 |
| Progesterone | 52 | $3,039 | $58 |
| Gabapentin | 31 | $506 | $16 |
| Clobetasol Propionate | 11 | $231 | $21 |
2020: 7 drugs
| Estradiol | 67 | $10,396 | $155 |
| Progesterone | 54 | $3,672 | $68 |
| Estradiol (Twice Weekly) | 12 | $2,195 | $183 |
| Estradiol (Once Weekly) | 24 | $1,917 | $80 |
| Gabapentin | 28 | $600 | $21 |
| Clobetasol Propionate | 15 | $457 | $30 |
| Sertraline | 12 | $109 | $9 |
2019: 3 drugs
| Estradiol | 76 | $9,518 | $125 |
| Progesterone | 51 | $4,109 | $81 |
| Gabapentin | 49 | $862 | $18 |
2018: 5 drugs
| Estradiol | 48 | $4,295 | $89 |
| Metronidazole | 20 | $1,336 | $67 |
| Progesterone | 15 | $797 | $53 |
| Medroxyprogesterone Acetate | 11 | $135 | $12 |
| Gabapentin | 15 | $130 | $9 |
2017: 4 drugs
| Prempro | 12 | $4,842 | $403 |
| Progesterone | 18 | $1,132 | $63 |
| Estradiol | 35 | $1,014 | $29 |
| Medroxyprogesterone Acetate | 14 | $172 | $12 |
2016: 5 drugs
| Vagifem | 14 | $4,879 | $348 |
| Combipatch | 15 | $2,524 | $168 |
| Progesterone | 21 | $1,505 | $72 |
| Estradiol | 35 | $580 | $17 |
| Medroxyprogesterone Acetate | 11 | $65 | $6 |
2015: 3 drugs
| Vagifem | 35 | $9,068 | $259 |
| Estrace | 11 | $2,239 | $204 |
| Estradiol | 24 | $598 | $25 |
2014: 3 drugs
| Vagifem | 44 | $7,060 | $160 |
| Estradiol | 12 | $200 | $17 |
| Acyclovir | 11 | $183 | $17 |
2013: 2 drugs
| Vagifem | 42 | $5,547 | $132 |
| Premarin | 15 | $1,661 | $111 |
Money from drug and device companies
$66 in 2023
A payment is not proof that care is biased.
| Astellas Pharma US | None | $66 | 1 payment
|
See the published payment
| Astellas Pharma US | Meals · 2023-09-26 | None | $66 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1922016484
- Licence
- CA G186905, OR MD16031California G186905: Current · expires 2027-06-30
- Trained
- University of Texas Medical School at Houston, 1988
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- OR 017652
- Taxonomy
- Federal specialty code 207VG0400X (207VG0400X); Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-03
- NPI last updated
- 2024-04-19
- NPI record certified
- 2024-04-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3181 Sw Sam Jackson Park Rd, Portland, OR, 97239